Multicenter diagnostic evaluation of a Novel Coronavirus Antigen Lateral Flow Test among symptomatic individuals in Brazil and the United Kingdom
<p>The COVID-19 pandemic has led to the commercialization of many antigen-based rapid diagnostic tests (Ag-RDTs), requiring independent evaluations. This report describes the clinical evaluation of the Novel Coronavirus 2019-nCoV Antigen Test (Colloidal Gold) (Beijing Hotgen Biotech Co., Ltd.)...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Journal article |
| Language: | English |
| Published: |
American Society for Microbiology
2022
|
| _version_ | 1826310878263246848 |
|---|---|
| author | Faffe, DS Byrne, RL Body, R Castiñeiras, TMP Castiñeiras, AP Finch, LS Kontogianni, K Bengey, D Galliez, RM Ferreira, OC Mariani, D da Silva, BO Ribeiro, SS de Vos, M Escadafal, C Adams, ER Tanuri, A Cubas Atienzar, AI |
| author2 | LSTM Diagnostic Group |
| author_facet | LSTM Diagnostic Group Faffe, DS Byrne, RL Body, R Castiñeiras, TMP Castiñeiras, AP Finch, LS Kontogianni, K Bengey, D Galliez, RM Ferreira, OC Mariani, D da Silva, BO Ribeiro, SS de Vos, M Escadafal, C Adams, ER Tanuri, A Cubas Atienzar, AI |
| author_sort | Faffe, DS |
| collection | OXFORD |
| description | <p>The COVID-19 pandemic has led to the commercialization of many antigen-based rapid diagnostic tests (Ag-RDTs), requiring independent evaluations. This report describes the clinical evaluation of the Novel Coronavirus 2019-nCoV Antigen Test (Colloidal Gold) (Beijing Hotgen Biotech Co., Ltd.), at two sites within Brazil and one in the United Kingdom. The collected samples (446 nasal swabs from Brazil and 246 nasopharyngeal samples from the UK) were analyzed by the Ag-RDT and compared to reverse transcription-quantitative PCR (RT-qPCR). Analytical evaluation of the Ag-RDT was performed using direct culture supernatants of SARS-CoV-2 strains from the wild-type (B.1), Alpha (B.1.1.7), Delta (B.1.617.2), Gamma (P.1), and Omicron (B.1.1.529) lineages. An overall sensitivity and specificity of 88.2% (95% confidence interval [CI], 81.3 to 93.3) and 100.0% (95% CI, 99.1 to 100.0), respectively, were obtained for the Brazilian and UK cohorts. The analytical limit of detection was determined as 1.0 × 10<sup>3</sup> PFU/mL (Alpha), 2.5 × 10<sup>2</sup> PFU/mL (Delta), 2.5 × 10<sup>3</sup> PFU/mL (Gamma), and 1.0 × 10<sup>3</sup> PFU/mL (Omicron), giving a viral copy equivalent of approximately 2.1 × 10<sup>4</sup> copies/mL, 9.0 × 10<sup>5</sup> copies/mL, 1.7 × 10<sup>6</sup> copies/mL, and 1.8 × 10<sup>5</sup> copies/mL for the Ag-RDT, respectively. Overall, while a higher sensitivity was claimed by the manufacturers than that found in this study, this evaluation finds that the Ag-RDT meets the WHO minimum performance requirements for sensitivity and specificity of COVID-19 Ag-RDTs. This study illustrates the comparative performance of the Hotgen Ag-RDT across two global settings and considers the different approaches in evaluation methods.</p>
<br>
<p><strong>IMPORTANCE</strong> Since the beginning of the SARS-CoV-2 pandemic, we have witnessed growing numbers of antigen rapid diagnostic tests (Ag-RDTs) being brought to market. In the United Kingdom, this was somewhat controlled indirectly as the government offered free tests from a small number of companies. However, as this has now ceased, individuals are responsible for their own acquisition of test kits. Similarly in Brazil, as of January 2022, pharmacies and other health care retailers are permitted to sell Ag-RDTs directly to the community. Many of these Ag-RDTs have not been externally evaluated, and results are not readily available to the public. Thus, there is now a need for a transparent evaluation of Ag-RDTs with both analytical and clinical evaluation. We present an independent review of the Novel Coronavirus 2019-nCoV Antigen Test (Colloidal Gold) (Beijing Hotgen Biotech Co., Ltd.), at two sites within Brazil and one in the United Kingdom.</p> |
| first_indexed | 2024-03-07T07:58:32Z |
| format | Journal article |
| id | oxford-uuid:176775fc-c025-4b09-895a-9a4ec13ffc47 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:58:32Z |
| publishDate | 2022 |
| publisher | American Society for Microbiology |
| record_format | dspace |
| spelling | oxford-uuid:176775fc-c025-4b09-895a-9a4ec13ffc472023-09-14T15:17:29ZMulticenter diagnostic evaluation of a Novel Coronavirus Antigen Lateral Flow Test among symptomatic individuals in Brazil and the United KingdomJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:176775fc-c025-4b09-895a-9a4ec13ffc47EnglishSymplectic ElementsAmerican Society for Microbiology2022Faffe, DSByrne, RLBody, RCastiñeiras, TMPCastiñeiras, APFinch, LSKontogianni, KBengey, DGalliez, RMFerreira, OCMariani, Dda Silva, BORibeiro, SSde Vos, MEscadafal, CAdams, ERTanuri, ACubas Atienzar, AILSTM Diagnostic GroupCONDOR Steering Group<p>The COVID-19 pandemic has led to the commercialization of many antigen-based rapid diagnostic tests (Ag-RDTs), requiring independent evaluations. This report describes the clinical evaluation of the Novel Coronavirus 2019-nCoV Antigen Test (Colloidal Gold) (Beijing Hotgen Biotech Co., Ltd.), at two sites within Brazil and one in the United Kingdom. The collected samples (446 nasal swabs from Brazil and 246 nasopharyngeal samples from the UK) were analyzed by the Ag-RDT and compared to reverse transcription-quantitative PCR (RT-qPCR). Analytical evaluation of the Ag-RDT was performed using direct culture supernatants of SARS-CoV-2 strains from the wild-type (B.1), Alpha (B.1.1.7), Delta (B.1.617.2), Gamma (P.1), and Omicron (B.1.1.529) lineages. An overall sensitivity and specificity of 88.2% (95% confidence interval [CI], 81.3 to 93.3) and 100.0% (95% CI, 99.1 to 100.0), respectively, were obtained for the Brazilian and UK cohorts. The analytical limit of detection was determined as 1.0 × 10<sup>3</sup> PFU/mL (Alpha), 2.5 × 10<sup>2</sup> PFU/mL (Delta), 2.5 × 10<sup>3</sup> PFU/mL (Gamma), and 1.0 × 10<sup>3</sup> PFU/mL (Omicron), giving a viral copy equivalent of approximately 2.1 × 10<sup>4</sup> copies/mL, 9.0 × 10<sup>5</sup> copies/mL, 1.7 × 10<sup>6</sup> copies/mL, and 1.8 × 10<sup>5</sup> copies/mL for the Ag-RDT, respectively. Overall, while a higher sensitivity was claimed by the manufacturers than that found in this study, this evaluation finds that the Ag-RDT meets the WHO minimum performance requirements for sensitivity and specificity of COVID-19 Ag-RDTs. This study illustrates the comparative performance of the Hotgen Ag-RDT across two global settings and considers the different approaches in evaluation methods.</p> <br> <p><strong>IMPORTANCE</strong> Since the beginning of the SARS-CoV-2 pandemic, we have witnessed growing numbers of antigen rapid diagnostic tests (Ag-RDTs) being brought to market. In the United Kingdom, this was somewhat controlled indirectly as the government offered free tests from a small number of companies. However, as this has now ceased, individuals are responsible for their own acquisition of test kits. Similarly in Brazil, as of January 2022, pharmacies and other health care retailers are permitted to sell Ag-RDTs directly to the community. Many of these Ag-RDTs have not been externally evaluated, and results are not readily available to the public. Thus, there is now a need for a transparent evaluation of Ag-RDTs with both analytical and clinical evaluation. We present an independent review of the Novel Coronavirus 2019-nCoV Antigen Test (Colloidal Gold) (Beijing Hotgen Biotech Co., Ltd.), at two sites within Brazil and one in the United Kingdom.</p> |
| spellingShingle | Faffe, DS Byrne, RL Body, R Castiñeiras, TMP Castiñeiras, AP Finch, LS Kontogianni, K Bengey, D Galliez, RM Ferreira, OC Mariani, D da Silva, BO Ribeiro, SS de Vos, M Escadafal, C Adams, ER Tanuri, A Cubas Atienzar, AI Multicenter diagnostic evaluation of a Novel Coronavirus Antigen Lateral Flow Test among symptomatic individuals in Brazil and the United Kingdom |
| title | Multicenter diagnostic evaluation of a Novel Coronavirus Antigen Lateral Flow Test among symptomatic individuals in Brazil and the United Kingdom |
| title_full | Multicenter diagnostic evaluation of a Novel Coronavirus Antigen Lateral Flow Test among symptomatic individuals in Brazil and the United Kingdom |
| title_fullStr | Multicenter diagnostic evaluation of a Novel Coronavirus Antigen Lateral Flow Test among symptomatic individuals in Brazil and the United Kingdom |
| title_full_unstemmed | Multicenter diagnostic evaluation of a Novel Coronavirus Antigen Lateral Flow Test among symptomatic individuals in Brazil and the United Kingdom |
| title_short | Multicenter diagnostic evaluation of a Novel Coronavirus Antigen Lateral Flow Test among symptomatic individuals in Brazil and the United Kingdom |
| title_sort | multicenter diagnostic evaluation of a novel coronavirus antigen lateral flow test among symptomatic individuals in brazil and the united kingdom |
| work_keys_str_mv | AT faffeds multicenterdiagnosticevaluationofanovelcoronavirusantigenlateralflowtestamongsymptomaticindividualsinbrazilandtheunitedkingdom AT byrnerl multicenterdiagnosticevaluationofanovelcoronavirusantigenlateralflowtestamongsymptomaticindividualsinbrazilandtheunitedkingdom AT bodyr multicenterdiagnosticevaluationofanovelcoronavirusantigenlateralflowtestamongsymptomaticindividualsinbrazilandtheunitedkingdom AT castineirastmp multicenterdiagnosticevaluationofanovelcoronavirusantigenlateralflowtestamongsymptomaticindividualsinbrazilandtheunitedkingdom AT castineirasap multicenterdiagnosticevaluationofanovelcoronavirusantigenlateralflowtestamongsymptomaticindividualsinbrazilandtheunitedkingdom AT finchls multicenterdiagnosticevaluationofanovelcoronavirusantigenlateralflowtestamongsymptomaticindividualsinbrazilandtheunitedkingdom AT kontogiannik multicenterdiagnosticevaluationofanovelcoronavirusantigenlateralflowtestamongsymptomaticindividualsinbrazilandtheunitedkingdom AT bengeyd multicenterdiagnosticevaluationofanovelcoronavirusantigenlateralflowtestamongsymptomaticindividualsinbrazilandtheunitedkingdom AT galliezrm multicenterdiagnosticevaluationofanovelcoronavirusantigenlateralflowtestamongsymptomaticindividualsinbrazilandtheunitedkingdom AT ferreiraoc multicenterdiagnosticevaluationofanovelcoronavirusantigenlateralflowtestamongsymptomaticindividualsinbrazilandtheunitedkingdom AT marianid multicenterdiagnosticevaluationofanovelcoronavirusantigenlateralflowtestamongsymptomaticindividualsinbrazilandtheunitedkingdom AT dasilvabo multicenterdiagnosticevaluationofanovelcoronavirusantigenlateralflowtestamongsymptomaticindividualsinbrazilandtheunitedkingdom AT ribeiross multicenterdiagnosticevaluationofanovelcoronavirusantigenlateralflowtestamongsymptomaticindividualsinbrazilandtheunitedkingdom AT devosm multicenterdiagnosticevaluationofanovelcoronavirusantigenlateralflowtestamongsymptomaticindividualsinbrazilandtheunitedkingdom AT escadafalc multicenterdiagnosticevaluationofanovelcoronavirusantigenlateralflowtestamongsymptomaticindividualsinbrazilandtheunitedkingdom AT adamser multicenterdiagnosticevaluationofanovelcoronavirusantigenlateralflowtestamongsymptomaticindividualsinbrazilandtheunitedkingdom AT tanuria multicenterdiagnosticevaluationofanovelcoronavirusantigenlateralflowtestamongsymptomaticindividualsinbrazilandtheunitedkingdom AT cubasatienzarai multicenterdiagnosticevaluationofanovelcoronavirusantigenlateralflowtestamongsymptomaticindividualsinbrazilandtheunitedkingdom |